[Pharmacokinetic study of S-1 for the treatment of peritoneal metastasis from colon cancer--using a mouse peritoneal metastasis model].
OBJECTIVE
To investigate the usefulness of S-1 for the treatment of peritoneal metastasis from colon cancer using a colon cancer peritoneal metastasis model.


METHODS
Colon 26 PMF-15 cells were transplanted intraperitoneally into mice. The concentrations of 5-fluorouracil (5-FU) and gimeracil (CDHP) in the plasma and peritoneal tissue of the mice were determined at 6 sampling time points, i. e., pre-dosing and at 30min, 1, 2, 4 and 8 hrs after oral administration of S-1 (10mg/kg equivalent of FT) on day 20 post-transplantation.


RESULTS
The AUC0-8h values of both 5-FU and CDHP were greater in the peritoneal tumor tissue than in the normal peritoneal tissue. The AUC of 5-FU in the peritoneal tumor tissue was 2. 90 times higher than that in plasma.


CONCLUSIONS
The results suggest that S-1 may exert an antitumor effect on peritoneal metastasis arising from colon cancer and be potentially useful as a therapeutic agent in cases of colon cancer with peritoneal metastasis, which is generally recognized as carrying an unfavorable prognosis.
Sadahiro
Sotaro
S
Dept. of Surgery, Tokai University, School of Medicine, Japan.
Suzuki
Toshiyuki
T
Maeda
Yuji
Y
Tanaka
Akira
A
Okada
Kazutake
K
Kanoda
Hisashi
H
Kamijo
Akemi
A
D000284:Administration, Oral; D000818:Animals; D045744:Cell Line, Tumor; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004195:Disease Models, Animal; D004338:Drug Combinations; D008297:Male; D051379:Mice; D009368:Neoplasm Transplantation; D010094:Oxonic Acid / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary; D005641:Tegafur / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use
D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid